# US 2019/0169158 A1 · Small Molecule Activators of Parkin Enzyme Function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169158 A1
- Document ID: US20190169158A1
- Status: Published application
- Kind: A1
- Application number: 16/321,208
- Filed: 2017-07-28
- Published: 2019-06-06
- Earliest claimed: 2016-07-28
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Wolfdieter Springer; Fabienne C. Fiesel; Thomas R. Caulfield
- Web page: https://patentgrep.com/patent/US20190169158A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 35/00: Antineoplastic agents
- C07D 213/56: Amides
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 235/16: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 257/04: Five-membered rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C12N 9/93: {Ligases (6)}
- C12Y 603/02019: Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure relates to compounds for activating the enzymatic activity of an E3 ubiquitin ligase and methods for treating a disease or disorder in a subject with diminished E3 ubiquitin ligase enzymatic activity. In some embodiments, the present disclosure provides a compound of Formula (I) or a compound of Formula (II) or pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is CH or O;
B is CH or N;
D is C or N;
E is CH or N;
W is C or N;
X is C or N;
Y is C or N;
Z is C or N;
R1 is H, C1-4 alkyl, phenyl, or hetAr1;
R2 is H;
R3 is H;
or R2 and R3, together with Y and X, form a 6-membered cycloalkyl ring;
R7 is H;
or, optionally, when n is 0, R1 and R7, together with the atoms to which they are attached, form a 6-membered cycloalkyl ring;
R4 is H, C1-4 alkyl, halogen, CF3, or phenyl;
R5 is H, C1-4 alkyl, C4-10 cycloalkyl, phenyl optionally substituted with halogen, (C1-3 alkyl)O(C4-6 cycloalkyl), O(C1-4 alkyl)(C4-6 cycloalkyl), S(C1-4 alkyl), S(C4-6 cycloalkyl), (C1-3 alkyl)(C4-9 hetCyc1), het Ar1, or O(phenyl) optionally substituted with CN;
R6 is H or C1-4 alkyl;
hetAr1 is a 6-membered heteroaryl ring having 1-3 ring nitrogen atoms optionally substituted with C1-4 alkyl;
hetCyc1 is a 6-10-membered bicyclic ring having at least one ring heteroatom which is nitrogen and at least one of the rings is aromatic;
m is 0 or 1;
n is 0 or 1;
p is 0 or 1; and
the dashed lines can be single or double bonds.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A is CH.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein B is CH.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, wherein B is N.

### Claim 5 (depends on 1)

The compound of claim 1, wherein A is O and B is N.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein D is C.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein D is N.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein E is CH.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein E is N.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, wherein W is N.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, wherein W is C.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein X is C.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein Y is C.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein Y is N.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The compound of any one of claims 1-14, wherein Z is N.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The compound of any one of claims 1-14, wherein Z is C.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, wherein R1 is H.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, wherein R1 is C1-4 alkyl or hetAr1.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, wherein R1 is methyl, isopropyl, phenyl, or pyridine.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, wherein R4 is H.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, wherein R4 is C1, CF3, methyl or phenyl.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, wherein R5 is H or phenyl optionally substituted with halogen.

### Claim 23 (depends on 22)

The compound of claim 22, where R5 is phenyl substituted with F.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, wherein R5 is (C1-3 alkyl)O(C4-6 cycloalkyl), O(C1-4 alkyl)(C4-6 cycloalkyl), or O(phenyl) optionally substituted with CN.

### Claim 25 (depends on 24)

The compound of claim 24, wherein C4-6 cycloalkyl is cyclopentyl or cyclohexyl.

### Claim 26 (depends on 24)

The compound of claim 24, wherein R5 is (C1-3 alkyl)O(cyclopentyl) or O(C1-4 alkyl)(C4-6 cyclohexyl).

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, wherein R5 is C1-4 alkyl, C4-10 cycloalkyl, or (C1-3 alkyl)(C4-9 hetCyc1).

### Claim 28 (depends on 27)

The compound of claim 27, wherein hetCyc1 is a 9-membered bicyclic ring having one or more nitrogen atoms.

### Claim 29 (depends on 28)

The compound of claim 28, wherein hetCyc1 is isoindoline.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, wherein R5 is S(C1-4 alkyl) or S(C4-6 cycloalkyl).

### Claim 31 (depends on 30)

The compound of claim 30, wherein C4-6 cycloalkyl is cyclopentyl or cyclohexyl.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, wherein R5 is hetAr1.

### Claim 33 (depends on 32)

The compound of claim 32, wherein hetAr1 is pyridine or pyrimidine optionally substituted with C1-4 alkyl.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound of any one of claims 1-33, wherein R6 is H.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The compound of any one of claims 1-34, wherein n is 0.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The compound of any one of claims 1-35, wherein m is 1.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The compound of any one of claims 1-36, wherein p is 0.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The compound of any one of claims 1-36, wherein p is 1.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, wherein the compound of Formula I is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 40

A compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
A is CH, N, or S;
B is CH, N, O, or S;
D is C or N;
E is CH or N;
L is C1-3 alkylene or C(═O);
W is CH, CH2, N, or NRa;
X is CH, CH2, N, or NRb;
Y is CH, CH2 or O;
Z is N or CR2′;
R1 is H or C1-3 alkyl;
R2 is absent or C1-6 alkylene;
R2′ is H or C1-6 alkyl;
or, when Z is CR2′, R2 and R2′, together with C, can be taken together to form a C1-6 heterocyclic ring;
R3 is H, halogen, C1-3 alkyl, C3-6 cycloalkyl, or C1-3 alkoxy;
R4 is H or C1-3 alkyl;
R4′ is H or C1-3 alkyl;
Ra is H or C1-3 alkyl;
Rb is C1-3 alkyl;
m is 0, 1 or 2;
n is 1 or 2;
p is 0 or 1; and
the dashed lines can be single or double bonds;
with the proviso that when n is 2, R1 is methyl, D is C, R3 is H, and A, B, and E are all CH, then at least one of W, X, and Y is not CH2.

### Claim 41 (depends on 40)

The compound of claim 40, wherein A is CH.

### Claim 42 (depends on 40)

The compound of claim 40, wherein A is N.

### Claim 43 (depends on 40)

The compound of claim 40, wherein A is S.

### Claim 44 (depends on 40, 41, 42, 43)

The compound of any one of claims 40-43, wherein B is CH.

### Claim 45 (depends on 40, 41, 42, 43)

The compound of any one of claims 40-43, wherein B is N, O, or S.

### Claim 46 (depends on 40, 41, 42, 43, 44, 45)

The compound of any one of claims 40-45, wherein D is C.

### Claim 47 (depends on 40, 41, 42, 43, 44, 45, 46)

The compound of any one of claims 40-46, wherein E is CH.

### Claim 48 (depends on 40, 41, 42, 43, 44, 45, 46)

The compound of any one of claims 40-46, wherein E is N.

### Claim 49 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 40-48, wherein L is C1-3 alkylene.

### Claim 50 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 40-48, wherein L is methylene.

### Claim 51 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The compound of any one of claims 40-50, wherein W is CH2.

### Claim 52 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The compound of any one of claims 40-50, wherein W is N.

### Claim 53 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The compound of any one of claims 40-52, wherein X is CH2.

### Claim 54 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The compound of any one of claims 40-52, wherein X is CH.

### Claim 55 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The compound of any one of claims 40-52, wherein X is NRb.

### Claim 56 (depends on 55)

The compound of claim 55, wherein Rb is methyl.

### Claim 57 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound of any one of claims 40-56, wherein Y is CH2.

### Claim 58 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound of any one of claims 40-56, wherein Y is CH.

### Claim 59 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The compound of any one of claims 40-58, wherein Z is N.

### Claim 60 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The compound of any one of claims 40-59, wherein R2 is absent.

### Claim 61 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The compound of any one of claims 40-58, wherein Z is CR2′.

### Claim 62 (depends on 61)

The compound of claim 61, wherein R2 and R2′, together with C, form a 5-membered heterocyclic ring having 1 nitrogen atom.

### Claim 63 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The compound of any one of claims 40-62, wherein R1 is H.

### Claim 64 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The compound of any one of claims 40-62, wherein R1 is methyl.

### Claim 65 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The compound of any one of claims 40-64, wherein Ra is H or methyl.

### Claim 66 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound of any one of claims 40-65, wherein Rb is methyl.

### Claim 67 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The compound of any one of claims 40-66, wherein R3 is H, halogen, or C3-6 cycloalkyl.

### Claim 68 (depends on 67)

The compound of claim 67, wherein R3 is chlorine.

### Claim 69 (depends on 67)

The compound of claim 67, wherein R3 is cyclopropyl.

### Claim 70 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The compound of any one of claims 40-69, wherein R4 and R4′ are each H.

### Claim 71 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The compound of any one of claims 40-69, wherein R4 and R4′ are each methyl.

### Claim 72 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The compound of any one of claims 40-71, wherein n is 1.

### Claim 73 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The compound of any one of claims 40-72, wherein n is 2.

### Claim 74 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The compound of any one of claims 40-73, wherein m is 1 or 2.

### Claim 75 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The compound of any one of claims 40-74, wherein p is 0.

### Claim 76 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The compound of any one of claims 40-74, wherein p is 1.

### Claim 77 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The compound of any one of claims 40-76, wherein the compound of Formula II is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 78 (depends on 40)

The compound of claim 40, wherein the compound of Formula II is a compound of Formula IIa:
or a pharmaceutically acceptable salt thereof, wherein:
A is CH or N;
B is N, O, or S;
D is C or N;
E is CH or N;
W is CH2 or NRa;
X is CH, CH2, N, or NRb;
Y is CH, CH2 or O;
L is C1-3 alkylene or C(═O);
R1 is H or C1-3 alkyl;
R3 is C1-3 alkyl or C1-3 alkoxy;
R4 is H or C1-3 alkyl;
R4′ is H or C1-3 alkyl;
Ra is H or C1-3 alkyl;
Rb is C1-3 alkyl;
n is 1 or 2;
m is 0, 1 or 2;
p is 0 or 1; and
the dashed lines can be single or double bonds.

### Claim 79 (depends on 40)

The compound of claim 40, wherein the compound of Formula II is a compound of Formula IIb:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-3 alkyl; and
R5 is (C1-3 alkyl)phenyl.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A pharmaceutical composition comprising a compound of any one of claims 1-79, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A method of activating the enzymatic activity of an E3 ubiquitin ligase in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-79, or a pharmaceutically acceptable salt thereof.

### Claim 82 (depends on 81)

The method of claim 81, wherein the E3 ubiquitin ligase is selected from the group consisting of Parkin, ARIH1 (HHARI), ARIH2 (TRIAD1), RNF31 (HOIP), RBCK1 (HOIL-1L), MUL1 (MAPL, MULAN), MARCH5 (MITOL), E3A, mdm2, anaphase-promoting complex (APC), UBR5 (EDD1), SOCS, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE4A, UBE4B, UBOX5, UBR5, WWP1, and WWP2.

### Claim 83 (depends on 81, 82)

The method of claim 81 or 82, wherein the enzymatic activity is activated or enhanced during mitochondrial stress.

### Claim 84 (depends on 81, 82, 83)

The method of any one of claims 81-83, wherein the compound stimulates mitochondrial quality control.

### Claim 85 (depends on 81, 82, 83, 84)

The method of any one of claims 81-84, wherein the compound interferes with the auto-inhibition of the ligase.

### Claim 86 (depends on 81, 82, 83, 84, 85)

The method of any one of claims 81-85, wherein the subject has diminished E3 ubiquitin ligase enzymatic activity.

### Claim 87 (depends on 86)

The method of claim 86, wherein the enzymatic activity is diminished due to a disease, aging, or an age-related disorder.

### Claim 88 (depends on 87)

The method of claim 87, wherein the disease or disorder is selected from the group consisting of Parkinson's disease, parkinsonism, Alzheimer's disease, dementia, Amyotrophic lateral sclerosis, Frontotemporal dementia, autism, depression, progeroid disorder, leprosy, an inclusion body myositis, diabetes mellitus, diabetic kidney disease, a liver disease, a lysosomal storage disorder, a neurological disease, a muscular disease, a mitochondrial disease, and cancer.

### Claim 89 (depends on 88)

The method of claim 88, wherein the disease or disorder is Parkinson's disease.

### Claim 90 (depends on 88)

The method of claim 88, wherein the disease or disorder is cancer.

### Claim 91 (depends on 90)

The method of claim 90, wherein the cancer is selected from the group consisting of liver cancer, brain cancer, skin cancer, kidney cancer, lung cancer, colon cancer, pancreatic cancer, hepatocellular carcinoma, glioma, skin cutaneous melanoma, clear cell renal cell carcinoma, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell cancer, colorectal cancer, pancreatic adenocarcinoma, adenoid cystic carcinoma, acute lymphoblastic leukemia, chronic myeloid leukemia, bladder urothelial cancer, head and neck squamous cell carcinoma, esophageal adenocarcinoma, gastric cancer, cervical cancer, thyroid cancer, and endometrioid cancer.

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A method of treating a disease or disorder associated with diminished E3 ubiquitin ligase enzymatic activity in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-79, or a pharmaceutically acceptable salt thereof.

### Claim 93 (depends on 92)

The method of claim 92, wherein the E3 ubiquitin ligase is selected from the group consisting of Parkin, ARIH1 (HHARI), ARIH2 (TRIAD1), RNF31 (HOIP), RBCK1 (HOIL-1L), MUL1 (MAPL, MULAN), MARCH5 (MITOL), E3A, mdm2, anaphase-promoting complex (APC), UBR5 (EDD1), SOCS, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE4A, UBE4B, UBOX5, UBR5, WWP1, and WWP2.

### Claim 94 (depends on 92, 93)

The method of claim 92 or 93, wherein the disease or disorder is selected from the group consisting of Parkinson's disease, parkinsonism, Alzheimer's disease, dementia, Amyotrophic lateral sclerosis, Frontotemporal dementia, autism, depression, progeroid disorder, leprosy, an inclusion body myositis, diabetes mellitus, diabetic kidney disease, a liver disease, a lysosomal storage disorder, a neurological disease, a muscular disease, a mitochondrial disease, and cancer.

### Claim 95 (depends on 94)

The method of claim 94, wherein the disease or disorder is Parkinson's disease.

### Claim 96 (depends on 94)

The method of claim 94, wherein the disease or disorder is cancer.

### Claim 97 (depends on 96)

The method of claim 96, wherein the cancer is selected from the group consisting of liver cancer, brain cancer, skin cancer, kidney cancer, lung cancer, colon cancer, pancreatic cancer, hepatocellular carcinoma, glioma, skin cutaneous melanoma, clear cell renal cell carcinoma, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell cancer, colorectal cancer, pancreatic adenocarcinoma, adenoid cystic carcinoma, acute lymphoblastic leukemia, chronic myeloid leukemia, bladder urothelial cancer, head and neck squamous cell carcinoma, esophageal adenocarcinoma, gastric cancer, cervical cancer, thyroid cancer, and endometrioid cancer.

### Claim 98 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A method of treating a disease or disorder in a subject, the method comprising:
(a) detecting a disease or disorder associated with diminished E3 ubiquitin ligase enzymatic activity; and
(b) administering to the subject a therapeutically effective amount of a compound of any one of claims 1-79, or a pharmaceutically acceptable salt thereof.

### Claim 99 (depends on 98)

The method of claim 98, wherein the E3 ubiquitin ligase is selected from the group consisting of Parkin, ARIH1 (HHARI), ARIH2 (TRIAD1), RNF31 (HOIP), RBCK1 (HOIL-1L), MUL1 (MAPL, MULAN), MARCH5 (MITOL), E3A, mdm2, anaphase-promoting complex (APC), UBR5 (EDD1), SOCS, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE4A, UBE4B, UBOX5, UBR5, WWP1, and WWP2.

### Claim 100 (depends on 98, 99)

The method of claim 98 or 99, wherein the disease or disorder is selected from the group consisting of Parkinson's disease, parkinsonism, Alzheimer's disease, dementia, Amyotrophic lateral sclerosis, Frontotemporal dementia, autism, depression, leprosy, an inclusion body myositis, diabetes mellitus, diabetic kidney disease, a liver disease, a lysosomal storage disorder, a neurological disease, a muscular disease, a mitochondrial disease, and cancer.

### Claim 101 (depends on 100)

The method of claim 100, wherein the disease or disorder is Parkinson's disease.

### Claim 102 (depends on 100)

The method of claim 100, wherein the disease or disorder is cancer.

### Claim 103 (depends on 102)

The method of claim 102, wherein the cancer is selected from the group consisting of liver cancer, brain cancer, skin cancer, kidney cancer, lung cancer, colon cancer, pancreatic cancer, hepatocellular carcinoma, glioma, skin cutaneous melanoma, clear cell renal cell carcinoma, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell cancer, colorectal cancer, pancreatic adenocarcinoma, adenoid cystic carcinoma, acute lymphoblastic leukemia, chronic myeloid leukemia, bladder urothelial cancer, head and neck squamous cell carcinoma, esophageal adenocarcinoma, gastric cancer, cervical cancer, thyroid cancer, and endometrioid cancer.

### Claim 104 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A method of treating Parkinson's disease in a subject, the method comprising:
(a) detecting Parkinson's disease in a subject; and
(b) administering to the subject a therapeutically effective amount of a compound of any one of claims 1-79, or a pharmaceutically acceptable salt thereof.

### Claim 105 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A method of treating an age-related disorder in a subject, the method comprising:
(a) detecting an age-related disorder in a subject; and
(b) administering to the subject a therapeutically effective amount of a compound of any one of claims 1-79, or a pharmaceutically acceptable salt thereof.

### Claim 106 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A method of treating cancer in a subject, the method comprising:
(a) detecting cancer in a subject; and
(b) administering to the subject a therapeutically effective amount of a compound of any one of claims 1-79, or a pharmaceutically acceptable salt thereof.

### Claim 107 (depends on 106)

The method of claim 106, wherein the cancer is selected from the group consisting of liver cancer, brain cancer, skin cancer, kidney cancer, lung cancer, colon cancer, pancreatic cancer, hepatocellular carcinoma, glioma, skin cutaneous melanoma, clear cell renal cell carcinoma, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell cancer, colorectal cancer, pancreatic adenocarcinoma, adenoid cystic carcinoma, acute lymphoblastic leukemia, chronic myeloid leukemia, bladder urothelial cancer, head and neck squamous cell carcinoma, esophageal adenocarcinoma, gastric cancer, cervical cancer, thyroid cancer, and endometrioid cancer.

### Claim 108 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A method of activating the enzymatic activity of an E3 ubiquitin ligase in a cell, the method comprising contacting the cell with a compound of any one of claims 1-79, or a pharmaceutically acceptable salt thereof.

### Claim 109 (depends on 108)

The method of claim 108, wherein the E3 ubiquitin ligase is selected from the group consisting of Parkin, ARIH1 (HHARI), ARIH2 (TRIAD1), RNF31 (HOIP), RBCK1 (HOIL-1L), MUL1 (MAPL, MULAN), MARCH5 (MITOL), E3A, mdm2, anaphase-promoting complex (APC), UBR5 (EDD1), SOCS, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE4A, UBE4B, UBOX5, UBR5, WWP1, and WWP2.

### Claim 110 (depends on 108, 109)

The method of claim 108 or 109, wherein the enzymatic activity is activated during mitochondrial stress.

### Claim 111 (depends on 108, 109, 110)

The method of any one of claims 108-110, wherein the compound stimulates mitochondrial quality control.

### Claim 112 (depends on 108, 109, 110, 111)

The method of any one of claims 108-111, wherein the compound interferes with the auto-inhibition of the ligase.

### Claim 113 (depends on 108, 109, 110, 111, 112)

The method of any one of claims 108-112, wherein the cell has diminished E3 ubiquitin ligase enzymatic activity.

### Claim 114 (depends on 108, 109, 110, 111, 112, 113)

The method of any one of claims 108-113, wherein the contacting is in vitro.
